Native human antibody to Shr promote mice survival after intraperitoneal challenge with invasive Group A Streptococcus.
Clicks: 169
ID: 111847
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.5
/100
169 views
39 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #140 of 432 articles by views in The Journal of infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
A vaccine against the group A streptococcus (GAS) has been actively pursued for decades. The surface receptor Shr is vital in GAS heme uptake and provides an effective target for active and passive immunization. Here, we isolated human monoclonal antibodies (mAbs) against Shr and evaluated their efficacy and mechanism.
| Reference Key |
chatterjee2020thenative
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Nilanjana Chatterjee;Ya-Shu Huang;Kristin V Lyles;Julie E Morgan;Lawrence M Kauvar;Susanna F Greer;Zehava Eichenbaum; |
| Journal | The Journal of infectious diseases |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.